`Case 1:24-cv-00053-TSK Document 20-2 Filed 07/03/24 Page 1of2 PagelD #: 2762
`
`EXHIBIT 2
`EXHIBIT 2
`
`
`
`Case 1:24-cv-00053-TSK Document 20-2 Filed 07/03/24 Page 2 of 2 PageID #: 2763
`
`
`
`JENNALEE N. BEAZLEY
`(202) 434-5767
`jbeazley@wc.com
`
`
`
`
`
`
`June 14, 2024
`
`
`
`Via Email
`John R. Labbe
`MARSHALL, GERSTEIN & BORUN LLP
`233 South Wacker Drive
`6300 Willis Tower
`(312) 474-6300
`jlabbe@marshallip.com
`
`Re:
`
`In re Aflibercept Patent Litigation, No. 1:24-md-03103-TSK
`Regeneron Pharms., Inc. v. Amgen Inc., No. 1:24-cv-00039-TSK (N.D.W. Va.)
`
`Counsel:
`
`Regeneron hereby produces documents bearing the following Bates numbers RGN-EYLEA-
`BIOSIM-AMG-00003797 - RGN-EYLEA-BIOSIM-AMG-00003826. This production consists
`of Mylan/Biocon’s redacted opposition brief.
`
`
`This production is password protected; the password is
`
`rAk?2U2HU=ri2*EKEhi@
`
`This document production will be made available for download on Williams & Connolly
`LLP’s secure file transfer site. You will receive an email with an invitation to join the site and
`download instructions shortly.
`
`
`
`
`
`
`
`
`
`Sincerely,
`
`/s/ Jennalee N. Beazley
`Jennalee N. Beazley
`
`